Publikationen in Zusammenarbeit mit Forschern von Ottawa Hospital (8)

2022

  1. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

    Blood, Vol. 140, Núm. 21, pp. 2248-2260

2021

  1. Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial

    Bone Marrow Transplantation, Vol. 56, Núm. 6, pp. 1413-1421

2018

  1. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

    Leukemia, Vol. 32, Núm. 8, pp. 1799-1803

2017

  1. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

    Leukemia and Lymphoma, Vol. 58, Núm. 12, pp. 2824-2832

2016

  1. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma

    Biology of Blood and Marrow Transplantation, Vol. 22, Núm. 10, pp. 1808-1815

  2. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study

    The Lancet, Vol. 387, Núm. 10020, pp. 770-778

2013

  1. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: A prospective randomized trial from the lymphoma working party of the European Group for Blood and Marrow Transplantation

    Journal of Clinical Oncology, Vol. 31, Núm. 13, pp. 1624-1630

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051